Single Use Technology Featured Articles

  1. Caliper's 'Lab On A Chip' Technology To Screen Neurocrine Assays 1/21/1999
    Caliper Technologies Corp. and Neurocrine Biosciences, Inc. are combining their drug discovery efforts to develop treatments for central nervous system and immune system diseases...
  2. Proof-Of-Principle For New Drug Development Tool 10/15/1998
    Miicro, Inc.'s results of its Phase I SBIR grant on metabolic neuroimaging for dose evaluation in clinical trials...
  3. Is There An Enzyme In Your Future? 8/25/1998
    A method for reducing the chemical steps in vitamin C synthesis from six to two underscores the growing importance of enzymes in organic synthesis...
  4. Ensure Integrity And Prevent Contamination In Single-Use Bags

    As single-use systems continue to gain in popularity, so does the use of single-use bags. A single contract manufacturer can use thousands of bags per year. Gallus Biopharmaceuticals has used over 40,000 bags in just the past decade. Due to the volume increases in some of these bags, the prevention of possible contamination issues has never been more important. More pharma manufacturers are now looking to perform point-of-use tests to ensure the integrity of the bags they are using.

  5. Life Science Insights From An Industry Visionary

    When Parrish Galliher first founded Xcellerex, now part of GE Healthcare, he referred to the business idea as “bugs on wheels” because unlike traditional stainless steel biologic manufacturing facilities which can’t be built quickly, easily changed or moved, his concept for the FlexFactory allowed manufacturers to build and/or modify manufacturing capacity quickly and at far less cost. Moreover, no longer did companies have to take three to four years to build a plant that could manufacture only one product, but could build structures that could be changed quickly from manufacturing one product to another. The idea was, at the time, quite disruptive to our conservative industry where, according to Galliher, it can take close to a decade for companies to adopt new technology. Galliher confided that in the early days of starting Xcellerex in December 2002, he struggled to get funding for the business.

  6. WIB Profile - bluebird bio Scientist On 10 Years Of Performing Tech Transfers

    Kelly Kral has worked in the pharmaceutical industry for more than 10 years. She started her career at Genzyme, working as a process engineer developing a fed batch process for the production of adenovirus in HEK293 suspension cells. Her responsibilities included media screening, cell growth characterization, and virus production in shake flasks, spinners, and bioreactors. She assisted in process transfer to a CMO and authored process documentation, skills she used extensively in her work as group leader for upstream process development at Percivia and in her current role of scientist I at bluebird bio.